title: Oral vaccination against plague using Yersinia pseudotuberculosis.
abstract: Yersinia pestis, the agent of plague, is among the deadliest bacterial pathogens affecting humans, and is a potential biological weapon. Because antibiotic resistant strains of Yersinia pestis have been observed or could be engineered for evil use, vaccination against plague might become the only means to reduce mortality. Although plague is re-emerging in many countries, a vaccine with worldwide license is currently lacking. The vaccine strategy described here is based on an oral vaccination with an attenuated strain of Yersinia pseudotuberculosis. Indeed, this species is genetically almost identical to Y. pestis, but has a much lower pathogenicity and a higher genomic stability. Gradual modifications of the wild-type Yersinia pseudotuberculosis strain IP32953 were performed to generate a safe and immunogenic vaccine. Genes coding for three essential virulence factors were deleted from this strain. To increase cross-species immunogenicity, an F1-encapsulated Y. pseudotuberculosis strain was then generated. For this, the Y. pestis caf operon, which encodes F1, was inserted first on a plasmid, and subsequently into the chromosome. The successive steps achieved to reach maximal vaccine potential are described, and how each step affected bacterial virulence and the development of a protective immune response is discussed. The final version of the vaccine, named VTnF1, provides a highly efficient and long-lasting protection against both bubonic and pneumonic plague after a single oral vaccine dose. Since a Y. pestis strain deprived of F1 exist or could be engineered, we also analyzed the protection conferred by the vaccine against such strain and found that it also confers full protection against the two forms of plague. Thus, the properties of VTnF1 makes it one of the most efficient candidate vaccine for mass vaccination in tropical endemic areas as well as for populations exposed to bioterrorism.
authors.affiliation: Unité de recherche Yersinia, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris, France. Electronic address: cdemeure@pasteur.fr.
authors.forename: Christian E
authors.initials: CE
authors.lastname: Demeure
authors.affiliation: Unité de recherche Yersinia, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris, France. Electronic address: anne.derbise@pasteur.fr.
authors.forename: Anne
authors.initials: A
authors.lastname: Derbise
authors.affiliation: Unité de recherche Yersinia, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris, France. Electronic address: elisabeth.carniel@pasteur.fr.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Carniel
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001426:Bacterial Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D010930:Plague / Q000517:prevention & control*; D010931:Plague Vaccine / Q000008:administration & dosage / Q000276:immunology*; D013552:Swine; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology; D014774:Virulence / Q000276:immunology; D015010:Yersinia pestis / Q000276:immunology*; D015011:Yersinia pseudotuberculosis / Q000276:immunology* / Q000378:metabolism
chemical_list: D001426:Bacterial Proteins; D010931:Plague Vaccine; D014614:Vaccines, Synthetic; C086725:caf1 protein, Yersinia pestis
keywords: Bubonic plague; F1 pseudocapsule; Live vaccine; Pneumonic plague; Yersinia pestis